Anbio Biotechnology (NNNN) shareholders
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.65−0.23 (-5.93%)
Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –
Ownership
Who owns Anbio Biotechnology's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Lau | CEO | – | – | Apr 8, 2026 |
| Chris Tian | CBO | – | – | Apr 8, 2026 |
| Suki Song | CFO | – | – | Apr 8, 2026 |
| Michael W.C Zhang | Director | – | – | Jun 12, 2026 |
| David H. Hsu | Director | – | – | Jun 12, 2026 |
| Cany Xu | Director | – | – | Apr 8, 2026 |
| Nancy Hartzler | Director | – | – | Apr 8, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.02%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+7.0%
From 0M shares
Short volume, 20 days
49.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Anbio Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,800 shares on Sep 23, 2026 over the last 90 days.
See a number that looks wrong?